Column Group Opportunity III, LP bought $12.0M of Surrozen (SRZN)
Executed Mar 26 2025, disclosed Mar 28 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 28 2025), the stock returned +0.4% (delay-adjusted); from the execution session (Mar 26 2025), -13.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Column Group Opportunity III, LP (10% owner) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in Surrozen, Inc. (SRZN). Across 1 priced purchase filing, the average 21-session return was -13.0% from execution and +0.4% from disclosure (delay-adjusted; derived). The largest single filing was $12.0M of SRZN (1,034,482 sh across 3 lots, as filed), executed Mar 26 2025.
Healthcare · Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→